Cargando…
Potential and Challenges of Induced Pluripotent Stem Cells in Liver Diseases Treatment
Tens of millions of patients are affected by liver disease worldwide. Many of these patients can benefit from cell therapy involving living metabolically active cells, either by treatment of their liver disease, or by prevention of their disease phenotype. Cell therapies, including hepatocyte transp...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449640/ https://www.ncbi.nlm.nih.gov/pubmed/26237490 http://dx.doi.org/10.3390/jcm3030997 |
_version_ | 1782373890615410688 |
---|---|
author | Yu, Yue Wang, Xuehao Nyberg, Scott L. |
author_facet | Yu, Yue Wang, Xuehao Nyberg, Scott L. |
author_sort | Yu, Yue |
collection | PubMed |
description | Tens of millions of patients are affected by liver disease worldwide. Many of these patients can benefit from cell therapy involving living metabolically active cells, either by treatment of their liver disease, or by prevention of their disease phenotype. Cell therapies, including hepatocyte transplantation and bioartificial liver (BAL) devices, have been proposed as therapeutic alternatives to the shortage of transplantable livers. Both BAL and hepatocyte transplantation are cellular therapies that avoid use of a whole liver. Hepatocytes are also widely used in drug screening and liver disease modelling. However, the demand for human hepatocytes, heavily outweighs their availability by conventional means. Induced pluripotent stem cells (iPSCs) technology brings together the potential benefits of embryonic stem cells (ESCs) (i.e., self-renewal, pluripotency) and addresses the major ethical and scientific concerns of ESCs: embryo destruction and immune-incompatibility. It has been shown that hepatocyte-like cells (HLCs) can be generated from iPSCs. Furthermore, human iPSCs (hiPSCs) can provide an unlimited source of human hepatocytes and hold great promise for applications in regenerative medicine, drug screening and liver diseases modelling. Despite steady progress, there are still several major obstacles that need to be overcome before iPSCs will reach the bedside. This review will focus on the current state of efforts to derive hiPSCs for potential use in modelling and treatment of liver disease. |
format | Online Article Text |
id | pubmed-4449640 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-44496402015-07-28 Potential and Challenges of Induced Pluripotent Stem Cells in Liver Diseases Treatment Yu, Yue Wang, Xuehao Nyberg, Scott L. J Clin Med Review Tens of millions of patients are affected by liver disease worldwide. Many of these patients can benefit from cell therapy involving living metabolically active cells, either by treatment of their liver disease, or by prevention of their disease phenotype. Cell therapies, including hepatocyte transplantation and bioartificial liver (BAL) devices, have been proposed as therapeutic alternatives to the shortage of transplantable livers. Both BAL and hepatocyte transplantation are cellular therapies that avoid use of a whole liver. Hepatocytes are also widely used in drug screening and liver disease modelling. However, the demand for human hepatocytes, heavily outweighs their availability by conventional means. Induced pluripotent stem cells (iPSCs) technology brings together the potential benefits of embryonic stem cells (ESCs) (i.e., self-renewal, pluripotency) and addresses the major ethical and scientific concerns of ESCs: embryo destruction and immune-incompatibility. It has been shown that hepatocyte-like cells (HLCs) can be generated from iPSCs. Furthermore, human iPSCs (hiPSCs) can provide an unlimited source of human hepatocytes and hold great promise for applications in regenerative medicine, drug screening and liver diseases modelling. Despite steady progress, there are still several major obstacles that need to be overcome before iPSCs will reach the bedside. This review will focus on the current state of efforts to derive hiPSCs for potential use in modelling and treatment of liver disease. MDPI 2014-09-05 /pmc/articles/PMC4449640/ /pubmed/26237490 http://dx.doi.org/10.3390/jcm3030997 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Yu, Yue Wang, Xuehao Nyberg, Scott L. Potential and Challenges of Induced Pluripotent Stem Cells in Liver Diseases Treatment |
title | Potential and Challenges of Induced Pluripotent Stem Cells in Liver Diseases Treatment |
title_full | Potential and Challenges of Induced Pluripotent Stem Cells in Liver Diseases Treatment |
title_fullStr | Potential and Challenges of Induced Pluripotent Stem Cells in Liver Diseases Treatment |
title_full_unstemmed | Potential and Challenges of Induced Pluripotent Stem Cells in Liver Diseases Treatment |
title_short | Potential and Challenges of Induced Pluripotent Stem Cells in Liver Diseases Treatment |
title_sort | potential and challenges of induced pluripotent stem cells in liver diseases treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449640/ https://www.ncbi.nlm.nih.gov/pubmed/26237490 http://dx.doi.org/10.3390/jcm3030997 |
work_keys_str_mv | AT yuyue potentialandchallengesofinducedpluripotentstemcellsinliverdiseasestreatment AT wangxuehao potentialandchallengesofinducedpluripotentstemcellsinliverdiseasestreatment AT nybergscottl potentialandchallengesofinducedpluripotentstemcellsinliverdiseasestreatment |